← Leaderboards
James Craig Hartman
Mdi Therapeutics, Inc.
$3,645,392
Attributed
$3,645,392
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,645,392 · 4
By mechanism
R44$3,203,631 · 2
R43$441,761 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Plasma”
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$26,214,655
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$25,721,506
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
Research focus
PlasmaPlasminogen Activator Inhibitor 1PhysiologicalPirfenidoneNovel TherapeuticsMouse ModelOralPharmaceutical PreparationsLeadPhysiologyMortalityFibrosisEtiologyHeart DiseasesFibrinolysisLung DiseasesInterestInnovationDrug CandidateIn VivoKidney DiseasesDoseHigh Throughput ScreeningPre-Clinical
Grant awards (6)
Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis$709,043
R44 · FY2023 · HL · contact PI
Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis$1,000,618
R44 · FY2022 · HL · contact PI
Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$746,985
R44 · FY2020 · AR · contact PI
Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$746,985
R44 · FY2019 · AR · contact PI
Preclinical development of a first in class therapeutic for treating idiopathic pulmonary fibrosis$225,000
R43 · FY2019 · HL · contact PI
Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$216,761
R43 · FY2018 · AR · contact PI